Colorectal Cancer - Pipeline Review, H2 2018

December 2018 | 2548 pages | ID: C17E15E283FEN
Global Markets Direct

Abstracts

Colorectal Cancer - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H2 2018, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 28, 157, 178, 17, 204, 39 and 13 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 23, 9, 1, 35 and 5 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Colorectal Cancer - Overview
Colorectal Cancer - Therapeutics Development
Colorectal Cancer - Therapeutics Assessment
Colorectal Cancer - Companies Involved in Therapeutics Development
Colorectal Cancer - Drug Profiles
Colorectal Cancer - Dormant Projects 2439
Colorectal Cancer - Discontinued Products 2462
Colorectal Cancer - Product Development Milestones 2468
Appendix 2479

List Of Tables

LIST OF TABLES

Number of Products under Development for Colorectal Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Colorectal Cancer - Pipeline by 3-V Biosciences Inc, H2 2018
Colorectal Cancer - Pipeline by 3SBio Inc, H2 2018
Colorectal Cancer - Pipeline by 4SC AG, H2 2018
Colorectal Cancer - Pipeline by Aadi Bioscience Inc, H2 2018
Colorectal Cancer - Pipeline by AB Science SA, H2 2018
Colorectal Cancer - Pipeline by AbbVie Inc, H2 2018
Colorectal Cancer - Pipeline by AbGenomics International Inc, H2 2018
Colorectal Cancer - Pipeline by Abpro, H2 2018
Colorectal Cancer - Pipeline by Aclaris Therapeutics Inc, H2 2018
Colorectal Cancer - Pipeline by Adamed Sp z oo, H2 2018
Colorectal Cancer - Pipeline by ADC Therapeutics SA, H2 2018
Colorectal Cancer - Pipeline by Adhera Therapeutics, H2 2018
Colorectal Cancer - Pipeline by Aduro BioTech Inc, H2 2018
Colorectal Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2018
Colorectal Cancer - Pipeline by Advanced BioDesign, H2 2018
Colorectal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018
Colorectal Cancer - Pipeline by Agency for Science, Technology and Research, H2 2018
Colorectal Cancer - Pipeline by Agenus Inc, H2 2018
Colorectal Cancer - Pipeline by AlfaSigma SpA, H2 2018
Colorectal Cancer - Pipeline by Alkermes Plc, H2 2018
Colorectal Cancer - Pipeline by Alligator Bioscience AB, H2 2018
Colorectal Cancer - Pipeline by Allinky Biopharma SL, H2 2018
Colorectal Cancer - Pipeline by Almac Discovery Ltd, H2 2018
Colorectal Cancer - Pipeline by Alpine Immune Sciences Inc, H2 2018
Colorectal Cancer - Pipeline by ALX Oncology Inc, H2 2018
Colorectal Cancer - Pipeline by Amarin Corp Plc, H2 2018
Colorectal Cancer - Pipeline by amcure GmbH, H2 2018
Colorectal Cancer - Pipeline by Amgen Inc, H2 2018
Colorectal Cancer - Pipeline by APEIRON Biologics AG, H2 2018
Colorectal Cancer - Pipeline by Apexigen Inc, H2 2018
Colorectal Cancer - Pipeline by Aphios Corp, H2 2018
Colorectal Cancer - Pipeline by Apogenix AG, H2 2018
Colorectal Cancer - Pipeline by Aposense Ltd, H2 2018
Colorectal Cancer - Pipeline by Arcus Biosciences Inc, H2 2018
Colorectal Cancer - Pipeline by Array BioPharma Inc, H2 2018
Colorectal Cancer - Pipeline by Arvinas Inc, H2 2018
Colorectal Cancer - Pipeline by Asana BioSciences LLC, H2 2018
Colorectal Cancer - Pipeline by Ascelia Pharma AB, H2 2018
Colorectal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018
Colorectal Cancer - Pipeline by Astellas Pharma Inc, H2 2018
Colorectal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2018
Colorectal Cancer - Pipeline by AstraZeneca Plc, H2 2018
Colorectal Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
Colorectal Cancer - Pipeline by Aurobindo Pharma Ltd, H2 2018
Colorectal Cancer - Pipeline by B Cell Design SAS, H2 2018
Colorectal Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2018
Colorectal Cancer - Pipeline by Batu Biologics Inc, H2 2018
Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2018
Colorectal Cancer - Pipeline by Bayer AG, H2 2018
Colorectal Cancer - Pipeline by BeiGene Ltd, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Colorectal Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

COMPANIES MENTIONED

3SBio Inc
3-V Biosciences Inc
4SC AG
Aadi Bioscience Inc
AB Science SA
AbbVie Inc
AbGenomics International Inc
Abpro
Aclaris Therapeutics Inc
Adamed Sp z oo
ADC Therapeutics SA
Adhera Therapeutics
Aduro BioTech Inc
Advanced Accelerator Applications SA
Advanced BioDesign
Advenchen Laboratories LLC
Agency for Science, Technology and Research
Agenus Inc
AlfaSigma SpA
Alkermes Plc
Alligator Bioscience AB
Allinky Biopharma SL
Almac Discovery Ltd
Alpine Immune Sciences Inc
ALX Oncology Inc
Amarin Corp Plc
amcure GmbH
Amgen Inc
APEIRON Biologics AG
Apexigen Inc
Aphios Corp
Apogenix AG
Aposense Ltd
Arcus Biosciences Inc
Array BioPharma Inc
Arvinas Inc
Asana BioSciences LLC
Ascelia Pharma AB
Aslan Pharmaceuticals Pte Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Aurobindo Pharma Ltd
B Cell Design SAS
Basilea Pharmaceutica Ltd
Batu Biologics Inc
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Beijing Hanmi Pharmaceutical Co Ltd
BeyondSpring Inc
Biocon Ltd
BioLineRx Ltd
Bionomics Ltd
Bionovis SA
Biosceptre International Ltd
BioXpress Therapeutics SA
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
CanBas Co Ltd
Cancer Prevention Pharmaceuticals Inc
Canget BioTekpharma LLC
Cantargia AB
Carna Biosciences Inc
CaroGen Corp
CBT Pharmaceuticals Inc
CCRP Therapeutics GmbH
Celgene Corp
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Celleron Therapeutics Ltd
Cellestia Biotech AG
Cellix Bio Pvt Ltd
Celltrion Inc
Celyad SA
Checkmate Pharmaceuticals Inc
Chengdu Kanghong Pharmaceuticals Group Co
Chiome Bioscience Inc
Chipscreen Biosciences Ltd
ChoDang Pharm Co Ltd
Chong Kun Dang Pharmaceutical Corp
Chugai Pharmaceutical Co Ltd
Cinnagen Co
Cleveland BioLabs Inc
COARE Biotechnology Inc
Compugen Ltd
Conatus Pharmaceuticals Inc
Corvus Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
Cytlimic Inc
Daiichi Sankyo Co Ltd
Deciphera Pharmaceuticals LLC
Dr. Reddy's Laboratories Ltd
eFFECTOR Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Endor Technologies SL
Enochian Biosciences Inc
EntreChem SL
Enzene Biosciences Ltd
Enzo Biochem Inc
EpiThany Inc
Etubics Corp
Evelo Biosciences Inc
Exelixis Inc
Exicure Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Fate Therapeutics Inc
FLX Bio Inc
Fog Pharmaceuticals Inc
Forbius
Formosa Laboratories Inc
Forty Seven Inc
Fresenius SE & Co KGaA
F-star Biotechnology Ltd
Fujifilm Holdings Corporation
Fusion Antibodies plc